MEDS Clinical Medicine (2024)
Clausius Scientific Press, Canada

DOI: 10.23977/medsc.2024.050424
ISSN 2616-1907 Vol. 5 Num. 4

Diagnostic Accuracy of the Gonorrhea Rapid Test Cassette: A Comparative Study with Culture Methods

Zhang Lei[1,*], Yang Feng[2], Zhu Junzhe[3]

[1]Zhejiang Gongshang University, Hangzhou, Zhejiang, 310018, China
[2]Community Health Service Center, Yipeng Street, Qiantang District, Hangzhou, Zhejiang, 310000, China
[3]Wenzhou Medical University, Wenzhou, Zhejiang, 310000, China
[*]Corresponding author: zhanglei@zjgsu.edu.cn

Keywords: Gonorrhea, Rapid Test, Diagnostics, Performance evaluation, Point of care

Abstract: This study evaluates the diagnostic efficacy of the Gonorrhea Rapid Test Cassette (Swab), a rapid chromatographic immunoassay designed for the qualitative detection of *Neisseria gonorrhoeae* in swab specimens from female cervical and male urethral sites. The research involved adult participants exhibiting symptoms of gonorrhea or deemed at high risk for sexually transmitted infections (STIs). Specimens were tested using the rapid test and the results were compared with those obtained from the culture method, which served as the reference standard. Key performance metrics—including sensitivity, specificity, positive predictive value, and negative predictive value—were calculated. The rapid test's capacity to deliver results in just 30 minutes enables prompt clinical decision-making, making it especially advantageous in resource-constrained environments. This study highlights the potential of the Gonorrhea Rapid Test Cassette to improve early detection and management of gonorrhea. It advocates for the integration of such rapid diagnostic tools into routine clinical practice to enhance public health outcomes in the prevention and control of STIs.

1. Introduction

Gonorrhea, caused by the bacterium *Neisseria gonorrhoeae*, is a significant global public health concern, resulting in substantial annual expenses for diagnosis and treatment.[1] In 2020, it was estimated that approximately 82.4 million new gonorrhea infections occurred among adults worldwide.[2] In women, symptoms of gonorrhea typically include vaginal discharge, discomfort or burning during urination and bleeding between menstrual periods or during sexual activity. Conversely, men who have gonorrhea commonly exhibit signs such as discharge from the penis, trouble with urination and pain or swelling in the testicles. It is important to note that while gonorrhea frequently remains asymptomatic in women, it usually produces more noticeable symptoms in men.[3] The lack of symptoms complicates the early identification of gonorrhea and heightens the likelihood of transmission. If left untreated, gonococcal infections will lead to significant complications and long-term effects in women, including pelvic inflammatory disease (PID), ectopic pregnancies and infertility.[4] In men, potential complications include scrotal swelling, urethral strictures and

infertility.[5] Furthermore, gonorrhea infection leads to social stigma and impact interpersonal relationships. Additionally, a diagnosis of gonorrhea is associated with an increased risk of acquiring HIV. [6]

N. gonorrhoeae is transmitted through vaginal, oral or anal sexual activity. Additionally, it can be transferred to a newborn during childbirth if the mother has an untreated genitourinary infection. There are notable regional disparities in the prevalence of gonorrhea. The World Health Organization reports that the highest rates occur in Africa, the Americas and the Pacific region, as well as among marginalized groups in developed countries.[7] Socioeconomic factors, healthcare availability and public health programs significantly influence these patterns. In resource-limited areas, understanding the local epidemiology of gonorrhea is essential for effectively tailoring prevention and treatment strategies.

Traditional diagnosis of gonorrhea relies on culture techniques, which, although cost-effective, are time-consuming and require specialized laboratory equipment. In contrast, nucleic acid amplification tests (NAAT) have emerged as a more sensitive and specific alternative, allowing for the detection of gonococci from a range of non-invasive specimens, including urine and vaginal or oropharyngeal swabs.[8] Nevertheless, this method is generally pricier than culture techniques and is primarily utilized in high-income regions.[8]

In recent years, the development of efficient rapid point-of-care tests (POCT) has emerged as a crucial priority for diagnosing gonorrhea.[9] These tests, frequently employing point-of-care (POC) technology, deliver results in less than an hour, enabling prompt initiation of treatment. Rapid diagnosis is particularly crucial in resource-limited settings, where access to comprehensive laboratory services is often restricted. [10] Quick turnaround times improve patient outcomes by reducing suffering and preventing further spread of infection. Compared to conventional methods, rapid tests offer significant advantages in terms of immediacy and patient care. While culture techniques may take several days to provide results and NAATs often require advanced laboratory equipment, the capacity of rapid tests to deliver results on-site enables healthcare providers to make timely clinical decisions. This is especially important in high-prevalence regions where the risks of complications and transmission are elevated. For instance, in a rural clinic, a rapid test quickly identifies infected individuals, allowing for the prompt administration of appropriate antibiotics without the delays associated with sending specimens to distant laboratories.

This research aims to evaluate the diagnostic efficacy of the Gonorrhea Rapid Test Cassette (Swab), a rapid chromatographic immunoassay designed for the qualitative detection of *Neisseria gonorrhoeae* in female cervical and male urethral specimens. By assessing the accuracy, sensitivity and specificity of this rapid testing method, the study seeks to determine its effectiveness in diagnosing gonorrhea infections. The results will enhance the understanding of the test's role in clinical settings, especially in situations where prompt diagnosis is essential for effective patient care and infection management.

2. Methods

2.1 Study Design and participants

In this study, specimens collected from patients at STD clinics were used to evaluate the effectiveness of a rapid gonorrhea test kit (swab) in a practical clinical setting. To be included, patients needed to either exhibit symptoms indicative of gonorrhea or be classified as high-risk based on their sexual history and relevant epidemiological factors.

2.2 Specimen Collection

Clinical specimens were collected from participants by trained healthcare professionals. For female participants, cervical swabs were obtained using sterile swabs, ensuring proper technique to minimize contamination. Male participants provided urethral swabs following standard guidelines to ensure specimen integrity. Each specimen was labeled and transported to the laboratory under appropriate conditions to maintain viability for testing.

2.3 Diagnostic Testing

The primary diagnostic method employed in this study was the Gonorrhea Rapid Test Cassette (Swab) developed by Hangzhou AllTest Biotech Co., Ltd, a rapid chromatographic immunoassay designed to detect *Neisseria gonorrhoeae*. Each specimen underwent testing according to the manufacturer's instructions. To extract gonorrhea antigen, 5 drops of Reagent 1 are added to the extraction tube and a swab is inserted. The swab is rotated 15 times and allowed to stand for 2 minutes. Then, 4 drops of Reagent 2 are added to the tube. The swab is swirled 15 times until the solution is clear with a slight color. After 1 minute, the swab is pressed against the tube, withdrawn and the liquid is transferred into the dropper. Finally, the test cassette is placed on a flat surface and 3 drops of extraction solution are added to the specimen wells. The results are read after 10 minutes, with no interpretation after 30 minutes. For a positive test result, a colored line appears on both the control (C) and test (T) lines, indicating that gonorrhea was detected in the specimen; for a negative test, only the control line appears, indicating that no gonorrhea antigen was detected in the specimen; and if the control line does not appear, the test is invalid and the procedure needs to be checked or retested.

2.4 Reference Standard

To assess the diagnostic performance of the rapid test, results were compared to a reference standard, which consisted of culture. Culture were performed on all specimens, providing a reliable comparison for evaluating the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the rapid test.

2.5 Statistical Analysis

Descriptive statistics were used to summarize participant characteristics and test results. The sensitivity and specificity of the Gonorrhea Rapid Test Cassette were calculated using standard formulas, with results compared to the culture reference standard. Confidence intervals (CIs) were computed for these metrics to evaluate the precision of the estimates.

3. Results

The evaluation of the gonorrhea rapid test's performance characteristics was conducted using specimens from female cervical swabs and male urethral swabs, with culture serving as the reference standard. For the female cervical swab specimens shown in Table 1, the rapid test exhibited a relative sensitivity of 94.4% (95% CI: 86.2%-98.4%), a relative specificity of 96.9% (95% CI: 91.3%-99.4%) and an overall accuracy of 95.9% (95% CI: 91.7%-98.3%). These findings indicate that the rapid test effectively identifies positive cases (sensitivity) and accurately rules out negative cases (specificity) among female patients.

As shown in Table 2, the gonorrhea rapid test for male urethral swab specimens showed a relative sensitivity of 91.6% (95% CI: 84.6%-96.1%), a relative specificity of 97.1% (95% CI: 91.7%-99.4%)

and an overall accuracy of 94.3% (95% CI: 90.2%-97.0%). These results imply that the rapid test also performs effectively in male patients, demonstrating high accuracy in both detecting and excluding the infection.

Table 1: Performance Characteristics of Gonorrhea Rapid Test (For Female Cervical Swab Specimens).

Method		Culture		Total Results
Gonorrhea Rapid Test Cassette (Swab)	Results	Positive	Negative	
	Positive	67	3	70
	Negative	4	95	99
Total Results		71	98	169

Relative Sensitivity: 94.4% (95%CI*: 86.2%-98.4%)
Relative Specificity: 96.9% (95%CI*: 91.3%-99.4%)
Overall Accuracy: 95.9% (95%CI*: 91.7%-98.3%)
*: Confidence Intervals

Table 2: Performance Characteristics of Gonorrhea Rapid Test (For Male Urethral Swab Specimens).

Method		Culture		Total Results
Gonorrhea Rapid Test Cassette (Swab)	Results	Positive	Negative	
	Positive	98	3	101
	Negative	9	100	109
Total Results		107	103	210

Relative Sensitivity: 91.6% (95%CI*: 84.6%-96.1%)
Relative Specificity: 97.1% (95%CI*: 91.7%-99.4%)
Overall Accuracy: 94.3% (95%CI*: 90.2%-97.0%)
*: Confidence Intervals

4. Discussion

4.1 Current Status of Rapid Tests in Gonorrhea Diagnosis

Globally, gonorrhea remains a prevalent STI, with rising antibiotic resistance posing a major public health challenge. Timely diagnosis and treatment are crucial, especially in high-risk populations. Rapid tests, such as the Gonorrhea Rapid Test Cassette, have garnered attention for their potential to deliver immediate results, enabling prompt treatment and reducing transmission. However, the adoption of such rapid tests varies significantly across regions and healthcare settings. In many developed countries, the uptake of rapid tests has been slow, largely due to the existing infrastructure for traditional laboratory-based diagnostics, which are often perceived as more reliable.[11] Conversely, in low-resource settings where access to laboratory facilities is limited, rapid tests present a viable solution for improving STI management.[12] By enabling healthcare providers to diagnose gonorrhea on-site, these tests significantly enhance patient care and improve public health outcomes.

4.2 Advantages of Rapid Diagnostic Tests

The primary advantage of the Gonorrhea Rapid Test Cassette lies in its ability to deliver results quickly—often within 30 minutes. This rapid turnaround time empowers clinicians to make immediate treatment decisions, which is crucial in preventing complications associated with untreated

infections, such as PID in women and epididymitis in men. Furthermore, rapid tests help streamline patient flow in busy clinical settings, reducing waiting times and improving overall patient satisfaction. Another significant benefit is the potential for increased screening and early detection. Many individuals with gonorrhea remain asymptomatic, particularly women, contributing to the spread of the infection. Rapid tests facilitate routine screening in high-risk populations, such as sexually active adolescents and young adults, helping to identify cases that might otherwise go undetected. Additionally, the Gonorrhea Rapid Test is designed for ease of use. Its straightforward protocol allows healthcare providers with minimal training to perform the test, making it accessible in a variety of settings, including community health clinics and outreach programs.[13]

4.3 Limitations and Challenges

Despite these advantages, rapid tests also have inherent limitations. One significant concern is their sensitivity and specificity in comparison to gold-standard diagnostic methods, such as culture and NAATs. While the rapid test provides timely results, it may not be as sensitive as NAATs, particularly in cases of low bacterial load. This raises the risk of false negatives, which could lead to missed diagnoses and subsequent transmission. Moreover, the Gonorrhea Rapid Test Cassette is currently limited to specific specimen types, such as cervical and urethral swabs. This restriction may impede its ability to detect infections at other anatomical sites, such as the throat or rectum, where gonorrhea also occurs. Expanding the test's applicability to these sites could enhance its overall utility. Another challenge is the need for ongoing education and training for healthcare providers. As rapid testing becomes more integrated into clinical practice, providers must be informed about the proper use of these tests, interpretation of results and appropriate follow-up procedures.

4.4 Future Directions and Optimization

To fully capitalize on the benefits of rapid diagnostic tests for gonorrhea, several strategies should be considered. First, ongoing research is essential to improve the sensitivity and specificity of rapid tests. Advances in assay technology could enhance the accuracy of detecting *Neisseria gonorrhoeae* across various specimen types. Additionally, integrating rapid testing into comprehensive sexual health services maximizes its impact. For example, implementing routine screening programs that utilize rapid tests facilitate early diagnosis and treatment, particularly in high-prevalence populations. Collaboration between public health organizations, healthcare providers, and community stakeholders will be crucial in designing and implementing these programs effectively. Furthermore, increasing awareness and education regarding rapid testing among both healthcare providers and patients is vital. Public health campaigns help destigmatize STIs and encourage individuals to seek testing and treatment. Educational initiatives should highlight the importance of regular screening and the advantages of rapid tests, particularly in settings with high rates of gonorrhea.

Looking ahead, the integration of rapid diagnostic tests into existing healthcare frameworks will be essential for combating gonorrhea. Policymakers should advocate for the inclusion of rapid testing in national STI management guidelines, especially in resource-limited settings. Investments in training healthcare workers and upgrading laboratory infrastructure will support the widespread adoption of these technologies. Moreover, ongoing surveillance of gonorrhea prevalence and antibiotic resistance patterns will be essential for informing testing strategies and treatment guidelines. As resistance continues to evolve, rapid tests must also adapt to ensure they remain effective tools for diagnosis.

5. Conclusion

In conclusion, the Gonorrhea Rapid Test Cassette (Swab) represents a valuable tool in the diagnostic landscape for gonorrhea, enabling faster identification of *Neisseria gonorrhoeae* and facilitating prompt treatment. This method addresses some challenges associated with traditional diagnostic techniques, particularly in resource-limited settings where laboratory access may be constrained. While the rapid test offers significant advantages in terms of speed and ease of use, it is important to be mindful of its limitations, such as potential issues with sensitivity and specificity. These aspects highlight the necessity for careful interpretation of results and, when appropriate, follow-up with confirmatory testing. Future directions should focus on improving the performance of rapid tests and broadening their applicability to various specimen types. Additionally, ongoing education for healthcare providers will be important for effective implementation in diverse clinical settings. Integrating rapid diagnostic tests into routine screening and treatment protocols, along with comprehensive public health strategies, may help address the ongoing challenges posed by gonorrhea and other sexually transmitted infections. A collaborative approach among healthcare providers and public health organizations could enhance efforts in STI prevention and management.

References

[1] Suay-Garcá B, Pérez-Gracia MT. Future Prospects for Neisseria gonorrhoeae Treatment. Antibiotics (Basel). 2018;7(2):49.

[2] Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. July 2013. Available:www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-6-eng.php#footnote-t1

[3] World Health Organization. (2024). Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services. World Health Organization. https://iris.who.int/handle/10665/378213. License: CC BY-NC-SA 3.0 IGO

[4] Cohen MS, Hoffman IF, Royce RA, et al. "Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1". The Lancet 1997;349:1868-1873.

[5] Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci. 2011;1230:E19-28.

[6] Fode M, Fusco F, Lipshultz L, Weidner W. Sexually transmitted disease and male infertility: a systematic review. Eur Urol Focus. 2016;2(4):383–393.

[7] Papp JRSJ, Gaydos CA, Van Der Pol, B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014. MMWR Recomm. Rep. 63, 1–19 (2014).

[8] Tabrizi SN, et al. Evaluation of six commercial nucleic acid amplification tests for detection of Neisseria gonorrhoeae and other Neisseria species. J. Clin. Microbiol. 2011, 49, 3610–3615.

[9] World Health Organization. Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae (World Health Organization, 2012).

[10] Pai M, Ghiasi M, Pai NP. Point-of-care diagnostic testing in global health: what is the point? Microbe 2015,10, 103–107.

[11] Peeling RW, Holmes KK, Mabey D, Ronald A. Rapid tests for sexually transmitted infections (STIs): The way forward. Sex Transm Infect. 2006;82(SUPPL. 5):1–6.

[12] Wi TEC, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, et al. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. Journal of the International AIDS Society 2019;22:e25343.

[13] Land KJ, Boeras DI, Chen X-S, Ramsay AR, Peeling RW. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. Nat Microbiol [Internet]. 2019;4(1):46–54.